<DOC>
	<DOCNO>NCT00391261</DOCNO>
	<brief_summary>The aim study evaluate effectiveness , safety , tolerability metformin treatment child adolescent suffer weight gain secondary use atypical antipsychotic medication . In 12 week , open-label study investigate metformin 's effect weight control and/or weight loss . We hypothesize metformin would prevent weight gain lead weight loss , result amelioration one significant side effect atypical antipsychotic use .</brief_summary>
	<brief_title>An Open-label Trial Metformin Weight Control Pediatric Patients Antipsychotic Medications .</brief_title>
	<detailed_description>Patients take olanzapine , risperidone , quetiapine increase BMI least 10 % previous 2 month atypical therapy eligible study . Subjects need stable dose antipsychotic medication time enrollment ( stable x2 week ) remain atypical dose , possible , throughout study . The dose metformin start 500mg per day increase maximum dose 1500mg daily . Determination weight gain course study base subject 's weight enrollment subsequent visit . The patient ask vary dietary physical activity habit study . Interpretation Data : The study 's primary outcome measure change weight body mass index 12 week metformin treatment . Additionally , skin-fold test abdominal girth measure baseline endpoint . Risks : Generally , metformin well-tolerated . However , may unknown risk associate exposure new medication clinical population specific compound study extensively . The general rare side effect list . These risk minimize careful monitoring high standard care safety evaluation . In addition , individual 's symptom could potentially remain unchanged worsen initiate medication , delay initiation potentially effective alternative treatment . For reason , participation study entirely voluntary consent may withdraw time without repercussion result patient immediately discontinue study . If time clinician believe patient benefiting study , study discontinue endpoint measure obtain possible . A risk-benefit analysis , weigh clinical improvement side effect do visit determine inclusion study . Subjects guardians ask repeatedly inform study staff side effect . Subjects informed potential side effect importance alert study staff side effect consent assent form . Side effect data collect baseline every week , subject encourage give relevant information every clinical evaluation . Alternative treatment include treatment attendant risk increase weight gain , potentially lead health hazard . Other medication available extensively use widely accept . These medication option discuss alternative consent process . Also , life-style modification include healthy diet habit increase physical activity discuss consent process well .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>1 . Males female age 1018 year . 2 . A DSMIV diagnosis bipolar disorder schizophrenia spectrum disorder , pervasive developmental disorder . 3 . Ability give assent . 4 . At least 10 % increase body mass index ( BMI ) within past 2 month quetiapine , olanzapine , risperidone treatment , per parent physician report . 5 . On stable dose quetiapine , olanzapine , risperidone x2 week . 6 . Otherwise medically stable . 1 . Subjects meet criterion eat disorder autistic spectrum disorder . 2 . IQ mild mental retardation range ( &lt; 60 ) , base verified record cognitive testing perform within 2 year enrollment . In event suitable record prior test unavailable , IQ estimate base current classroom placement . 3 . Significant medical and/or neurological illness , include seizure disorder , severe respiratory illness cardiac condition ; cerebrovascular disease ; hypo hypertension ; immune , endocrine , renal , hepatic dysfunction . The definition dysfunction derive laboratory normal range , value lie outside range would consider abnormal . 4 . Subjects take antidepressant . 5 . Active substance abuse/dependence base upon history and/or urine toxicology test perform screen . 6 . Inability blood drawn baseline , weekly , termination visit . 7 . Known allergy hypersensitivity metformin ingredient . 8 . Recent history suicidality , suicidal ideation , suicide attempt . 9 . Patients clinically unstable current medication regimen .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>weight gain</keyword>
	<keyword>obesity</keyword>
	<keyword>metabolism</keyword>
</DOC>